Product Description
Mechanisms of Action: CFTR Stabilizer
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sionna Therapeutics, Inc
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia
Active Clinical Trial Count: 3
Highest Development Phases
Phase 1: Cystic Fibrosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ACTRN12624000848505 | P1 |
Not yet recruiting |
Cystic Fibrosis |
None |
|
| ACTRN12624000849594 | P1 |
Not yet recruiting |
Cystic Fibrosis |
None |
|
| ACTRN12624000739516 | P1 |
Not yet recruiting |
Cystic Fibrosis |
None |